Participants received weekly injections of the highest tolerated doses of Zepbound, either 10 milligrams or 15 milligrams, or Wegovy, 1.7 milligrams or 2.4 milligrams. By the end of the trial ...

The company is preparing a Phase 3 trial of enobosarm with a novel formulation that could extend its patent life.

trial participants received weekly injections of the highest tolerated doses of Zepbound, either 10 milligrams or 15 milligrams, or Wegovy, 1.7 milligrams or 2.4 milligrams. When the trial ...

The company announced the detailed results from SURMOUNT-5, a Phase 3b open-label clinical trial ... reduction of 7.2 in (18.4 cm), while those treated with Wegovy saw an average reduction ...